Literature DB >> 25296747

Can we use enthesis ultrasound as an outcome measure of disease activity in spondyloarthritis? A study at the Achilles level.

Sandra Falcao1, Concepción Castillo-Gallego2, Diana Peiteado2, Jaime Branco3, Emilio Martín Mola2, Eugenio de Miguel2.   

Abstract

OBJECTIVE: The aim of this study was to evaluate the construct validity of enthesis US in the assessment of disease activity in SpA.
METHODS: A longitudinal Achilles enthesis US study in patients with early SpA was undertaken. Achilles US examinations were performed at baseline, 6 and 12 months and compared with clinical outcome measures collected at the baseline visit.
RESULTS: Bilateral Achilles enthesis of 146 early SpA patients (68 women) were analysed. Basal mean BASFI, BASRI-spine, BASDAI and Ankylosing Spondylitis Disease Activity Score (ASDAS) were 2.44 (s.d. 2.05, range 0-8), 0.67 (s.d. 0.74, range 0-3), 4.60 (s.d. 2.07, range 0-9.5) and 2.51 (s.d. 1.16, range 0-5), respectively. The mean ESR was 15.0 mm/h (s.d. 16.99, range 0-109) and the mean CRP was 8.67 mg/l (s.d. 16.98, range 1-90). At baseline, the Achilles Doppler signal and US structure alteration were significantly associated with higher CRP and ESR levels. Patients who had very high disease activity at baseline, as assessed by the ASDAS (>3.5), had a significantly higher Achilles total US score at baseline (P = 0.04), and ASDAS <1.3 predicted no Doppler signal at 6 and 12 months. Overall, the Achilles total US score was significantly higher in patients with higher levels of CRP (baseline P = 0.04, 6 months P = 0.006, 12 months P = 0.03) and ESR (baseline P = 0.02, 6 months P = 0.04, 12 months P = 0.005) at baseline. The Doppler signal at the baseline visit predicted a higher total US score at 6 and 12 months.
CONCLUSION: Doppler US has significant associations with other commonly accepted disease activity measures, such as ESR, CRP and ASDAS, and seems to be an objective outcome measure for enthesitis.
© The Author 2014. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  disease activity; spondyloarthritis; ultrasonography

Mesh:

Substances:

Year:  2014        PMID: 25296747     DOI: 10.1093/rheumatology/keu399

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  6 in total

1.  Strain Ultrasound Elastography in the Achilles Tendon of Ankylosing Spondylitis Patients Treated With Anti-TNF-α: A Preliminary Study.

Authors:  Enrico M Zardi; Maria Elena Pipita; Chiara Giorgi; Antonella Afeltra; Nicola Maffulli; Francesco Franceschi
Journal:  In Vivo       Date:  2019 Sep-Oct       Impact factor: 2.155

2.  Ultrasound in sacroiliitis: the picture is shaping up.

Authors:  Marwin Gutierrez; Carlos Pineda
Journal:  Rheumatol Int       Date:  2017-10-30       Impact factor: 2.631

3.  Features of the Achilles tendon, paratenon, and enthesis in inflammatory rheumatic diseases : A clinical and ultrasonographic study.

Authors:  H Harman; E Süleyman
Journal:  Z Rheumatol       Date:  2018-08       Impact factor: 1.372

Review 4.  Entheseal involvement in systemic disorders.

Authors:  Gleb Slobodin; Doron Rimar; Nina Boulman; Lisa Kaly; Michael Rozenbaum; Itzhak Rosner; Majed Odeh
Journal:  Clin Rheumatol       Date:  2015-09-10       Impact factor: 2.980

5.  Relationships between ultrasound enthesitis, disease activity and axial radiographic structural changes in patients with early spondyloarthritis: data from DESIR cohort.

Authors:  Adeline Ruyssen-Witrand; Bénédicte Jamard; Alain Cantagrel; Delphine Nigon; Damien Loeuille; Yannick Degboe; Arnaud Constantin
Journal:  RMD Open       Date:  2017-09-07

6.  Clinical assessment and ultrasonography in the follow-up of enthesitis in patients with spondyloarthritis: a multicenter ultrasound study in daily clinical practice.

Authors:  Wolfgang Hartung; Axel Nigg; Johannes Strunk; Björn Wolff
Journal:  Open Access Rheumatol       Date:  2018-12-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.